Investor Insight InMed is a pharmaceutical drug development company advancing proprietary small-molecule drugs in Alzheimer’s…
Category:
Investing
-
-
A mounting artificial intelligence (AI) bubble, overvalued markets and resource nationalism are among the issues…
-
Astral Resources (AAR:AU) has announced Theia In-fill – Multiple High-Grade Zones of Gold Download the…
-
Graphite One (TSXV:GPH,OTCQX:GPHOF) announced on November 13 that it has identified rare earth elements (REEs)…
-
Green Technology Metals(GT1:AU) has announced Ontario Lithium Project Development Update Download the PDF here. This…
-
East Star Resources (LSE:EST) and Endeavour Exploration announced they have entered into a binding earn-in…
-
Researchers have documented the first known recovery of naturally formed nanoscale monazite from a living…
-
Rio Tinto (ASX:RIO,NYSE:RIO,LSE:RIO) said on Monday (November 17) that it has signed a joint development…
-
Investing
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer’s Disease Candidate INM-901
by adminData will support design and planning of first in human clinical trials Preparing for pre-IND…
-
Skyharbour Resources Ltd. (TSX-V: SYH ) (OTCQX: SYHBF ) (Frankfurt: SC1P ) (‘Skyharbour’ or the…